CCM Investment Group LLC acquired a new position in shares of Medtronic PLC (NYSE:MDT - Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 62,546 shares of the medical technology company's stock, valued at approximately $5,481,000.
A number of other large investors have also recently made changes to their positions in the stock. Dunhill Financial LLC boosted its position in shares of Medtronic by 17.2% in the 1st quarter. Dunhill Financial LLC now owns 847 shares of the medical technology company's stock valued at $76,000 after purchasing an additional 124 shares during the period. Cidel Asset Management Inc. increased its position in Medtronic by 1.3% in the 1st quarter. Cidel Asset Management Inc. now owns 9,531 shares of the medical technology company's stock worth $856,000 after buying an additional 126 shares during the period. Petros Family Wealth LLC increased its position in shares of Medtronic by 4.3% during the first quarter. Petros Family Wealth LLC now owns 3,111 shares of the medical technology company's stock valued at $280,000 after purchasing an additional 127 shares during the period. Motco grew its position in Medtronic by 27.0% in the first quarter. Motco now owns 635 shares of the medical technology company's stock valued at $57,000 after acquiring an additional 135 shares during the period. Finally, Baker Avenue Asset Management LP boosted its stake in Medtronic by 3.1% in the first quarter. Baker Avenue Asset Management LP now owns 4,558 shares of the medical technology company's stock worth $410,000 after purchasing an additional 136 shares in the last quarter. 82.06% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
Several equities analysts have recently issued reports on MDT shares. Leerink Partnrs raised Medtronic to a "strong-buy" rating in a research note on Monday, June 16th. Mizuho upped their price target on Medtronic from $98.00 to $100.00 and gave the company an "outperform" rating in a research note on Wednesday, July 16th. Leerink Partners started coverage on Medtronic in a report on Monday, June 16th. They issued an "outperform" rating and a $110.00 price objective for the company. William Blair upgraded Medtronic to a "hold" rating in a report on Friday, July 11th. Finally, Morgan Stanley restated an "overweight" rating and issued a $107.00 price target (up from $98.00) on shares of Medtronic in a report on Tuesday, July 15th. Twelve research analysts have rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Medtronic has an average rating of "Moderate Buy" and a consensus price target of $98.19.
Read Our Latest Stock Analysis on Medtronic
Medtronic Stock Performance
NYSE:MDT traded up $0.81 during mid-day trading on Wednesday, hitting $92.89. 6,594,841 shares of the stock were exchanged, compared to its average volume of 7,637,530. The stock has a market capitalization of $119.07 billion, a price-to-earnings ratio of 25.66, a price-to-earnings-growth ratio of 2.41 and a beta of 0.80. The firm's 50-day simple moving average is $88.96 and its 200 day simple moving average is $87.97. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.42 and a current ratio of 1.85. Medtronic PLC has a fifty-two week low of $79.29 and a fifty-two week high of $96.25.
Medtronic (NYSE:MDT - Get Free Report) last issued its quarterly earnings results on Wednesday, May 21st. The medical technology company reported $1.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.58 by $0.04. Medtronic had a return on equity of 14.54% and a net margin of 13.90%. The company had revenue of $8.93 billion for the quarter, compared to analyst estimates of $8.81 billion. During the same quarter last year, the company posted $1.46 EPS. The company's revenue for the quarter was up 3.9% compared to the same quarter last year. As a group, equities analysts anticipate that Medtronic PLC will post 5.46 EPS for the current fiscal year.
Medtronic Increases Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Friday, July 11th. Stockholders of record on Friday, June 27th were paid a $0.71 dividend. The ex-dividend date of this dividend was Friday, June 27th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.1%. This is a positive change from Medtronic's previous quarterly dividend of $0.70. Medtronic's dividend payout ratio (DPR) is presently 78.45%.
Medtronic Company Profile
(
Free Report)
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.
Recommended Stories

Before you consider Medtronic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medtronic wasn't on the list.
While Medtronic currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.